Given that our results suggest that amplification alone will not always predict sensitivity to FGFR1 inhibition, additional work is needed to fully characterize the genetic alterations involved in NSCLC carcinogenesis and dependency on FGFR1. The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.